IMMUNOHISTOCHEMISTRY BLADDER VS PROSTATE CARCINOMA PANEL Test
Test Cost: AED 1170.0
Test Components:
- Price: 1170.0 AED
Sample Condition:
Submit tumor tissue in 10% Formal-saline OR Formalin fixed paraffin embedded block. Ship at room temperature. Provide a copy of the Histopathology report, Site of biopsy and Clinical history.
Report Delivery:
- Sample: Daily by 6 pm
- Report Block: 5 days
- Tissue Biopsy: 5 days
- Tissue large complex: 7 days
Method: Immunohistochemistry
Test Type: Cancer
Doctor: Oncologist, Pathologist
Test Department: HISTOLOGY
Pre Test Information:
Provide a copy of the Histopathology report, Site of biopsy and Clinical history.
Test Details:
The immunohistochemistry (IHC) bladder vs prostate carcinoma panel test is a diagnostic tool used to differentiate between bladder carcinoma and prostate carcinoma. It involves the use of specific antibodies that target certain proteins expressed in these two types of cancer cells. The panel typically includes a combination of antibodies that are specific to markers found in bladder carcinoma and prostate carcinoma cells. These markers help identify the origin of the tumor and aid in making an accurate diagnosis.
For bladder carcinoma, the panel may include antibodies against markers such as CK20 (cytokeratin 20), GATA3, and p63. CK20 is typically expressed in bladder cancer cells but not in prostate cancer cells. GATA3 and p63 are also commonly expressed in bladder carcinoma.
For prostate carcinoma, the panel may include antibodies against markers such as PSA (prostate-specific antigen), PSAP (prostatic acid phosphatase), and P501S (prostein). These markers are typically expressed in prostate cancer cells but not in bladder cancer cells.
By analyzing the expression of these markers in the tumor tissue using immunohistochemistry, pathologists can determine whether the cancer originated in the bladder or the prostate. This information is crucial for appropriate treatment planning and management of the patient.
It is important to note that the specific antibodies included in the panel may vary depending on the laboratory and the preferences of the pathologist. Additionally, other markers may be added to the panel if needed to further clarify the diagnosis.
Test Name | IMMUNOHISTOCHEMISTRY BLADDER VS PROSTATE CARCINOMA PANEL Test |
---|---|
Components | |
Price | 1170.0 AED |
Sample Condition | Submit tumor tissue in 10% Formal-saline OR Formalin fixed paraffin embedded block. Ship at room temperature. Provide a copy of the Histopathology report, Site of biopsy and Clinical history. |
Report Delivery | Sample Daily by 6 pm; Report Block : 5 days Tissue Biopsy : 5 days Tissue large complex : 7 days |
Method | Immunohistochemistry |
Test type | Cancer |
Doctor | Oncologist, Pathologist |
Test Department: | HISTOLOGY |
Pre Test Information | Provide a copy of the Histopathology report, Site of biopsy and Clinical history. |
Test Details |
The immunohistochemistry (IHC) bladder vs prostate carcinoma panel test is a diagnostic tool used to differentiate between bladder carcinoma and prostate carcinoma. It involves the use of specific antibodies that target certain proteins expressed in these two types of cancer cells. The panel typically includes a combination of antibodies that are specific to markers found in bladder carcinoma and prostate carcinoma cells. These markers help identify the origin of the tumor and aid in making an accurate diagnosis. For bladder carcinoma, the panel may include antibodies against markers such as CK20 (cytokeratin 20), GATA3, and p63. CK20 is typically expressed in bladder cancer cells but not in prostate cancer cells. GATA3 and p63 are also commonly expressed in bladder carcinoma. For prostate carcinoma, the panel may include antibodies against markers such as PSA (prostate-specific antigen), PSAP (prostatic acid phosphatase), and P501S (prostein). These markers are typically expressed in prostate cancer cells but not in bladder cancer cells. By analyzing the expression of these markers in the tumor tissue using immunohistochemistry, pathologists can determine whether the cancer originated in the bladder or the prostate. This information is crucial for appropriate treatment planning and management of the patient. It is important to note that the specific antibodies included in the panel may vary depending on the laboratory and the preferences of the pathologist. Additionally, other markers may be added to the panel if needed to further clarify the diagnosis. |